Consia Pharmaceuticals

Consia Pharmaceuticals is a Danish biotechnology company specializing in the development of a proprietary platform for the targeted delivery of therapeutics using sialic acid conjugation. Known as the ConSia platform, this technology exploits the interaction between sialic acids and Siglec receptors to modulate immune responses and improve the pharmacological profile of drugs. The company primarily focuses on addressing unmet needs in inflammatory and autoimmune diseases by enhancing the precision and efficacy of peptides and proteins. Consia's approach aims to reduce systemic side effects while maximizing therapeutic impact at the site of disease. The company was founded by industry veterans and has received backing from prominent Nordic life science investors like Seed Capital and Novo Holdings.